Why the study?
Does the potassium channel opener nicorandil reduce early afterdepolarizations and prevent syncopal episodes in a patient with idiopathic long QT syndrome?
Does the potassium channel opener nicorandil reduce early afterdepolarizations and prevent syncopal episodes in a patient with idiopathic long QT syndrome?
The potassium channel opener nicorandil successfully abolished early afterdepolarizations and prevented recurrent ventricular fibrillation in a patient with idiopathic long QT syndrome.
No takes yet. Share an insight, caveat, or question.
May benefit refractory idiopathic long QT syndrome cases; leaves open confirmation in prospective trials.
Sato et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: